vtv therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. we have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.
Company profile
Ticker
VTVT
Exchange
Website
CEO
Stephen Holcombe
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
VTV Therapeutics Inc.
SEC CIK
Corporate docs
Subsidiaries
vTv Therapeutics Inc. • vTv Therapeutics LLC ...
VTVT stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
25 Apr 24
S-3
Shelf registration
10 Apr 24
8-K
Other Events
26 Mar 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Results of Operations and Financial Condition
13 Mar 24
D
$50.96 mm in equity / options, sold $50.96 mm, 4 investors
7 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Feb 24
424B5
Prospectus supplement for primary offering
28 Feb 24
Latest ownership filings
SC 13D/A
MacAndrews & Forbes Inc.
22 Mar 24
3
Anne M. Phillips
14 Mar 24
4
JULIAN BAKER
7 Mar 24
3
JULIAN BAKER
7 Mar 24
3
Raymond Cheong
7 Mar 24
SC 13D
Samsara BioCapital, L.P.
5 Mar 24
SC 13D
BAKER BROS. ADVISORS LP
5 Mar 24
3
Initial statement of insider ownership
29 Feb 24
4
SRINIVAS AKKARAJU
29 Feb 24
3
SRINIVAS AKKARAJU
29 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.24 mm | 8.24 mm | 8.24 mm | 8.24 mm | 8.24 mm | 8.24 mm |
Cash burn (monthly) | 1.45 mm | 591.75 k | 2.85 mm | 2.53 mm | 1.61 mm | 1.92 mm |
Cash used (since last report) | 10.10 mm | 4.11 mm | 19.78 mm | 17.55 mm | 11.20 mm | 13.35 mm |
Cash remaining | -1.86 mm | 4.13 mm | -11.54 mm | -9.31 mm | -2.96 mm | -5.11 mm |
Runway (months of cash) | -1.3 | 7.0 | -4.1 | -3.7 | -1.8 | -2.7 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 0 |
Closed positions | 5 |
Increased positions | 4 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 2.64 bn |
Total shares | 80.73 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MacAndrews & Forbes | 61.43 mm | $33.86 mm |
G42 Investments AI Holdings RSC | 10.39 mm | $5.73 mm |
Medpace Investors | 5.40 mm | $6.53 mm |
Samsara BioCapital | 1.64 mm | $1.21 bn |
Vanguard | 939.62 k | $695.13 mm |
Geode Capital Management | 289.35 k | $214.06 mm |
Veritable | 242.94 k | $179.73 mm |
STT State Street | 134.75 k | $99.68 mm |
Susquehanna International | 76.25 k | $56.41 mm |
BLK Blackrock | 55.13 k | $40.79 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Mar 24 | Baker Bros. Advisors | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 52,881 | 0.00 | 89,254 |
5 Mar 24 | Baker Bros. Advisors | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 4,776 | 0.00 | 8,060 |
5 Mar 24 | Baker Bros. Advisors | Prefunded Warrants Common Stock | Grant | Acquire A | Yes | No | 0.01 | 52,925 | 529.25 | 2,823,061 |
5 Mar 24 | Baker Bros. Advisors | Prefunded Warrants Common Stock | Grant | Acquire A | Yes | No | 0.01 | 4,780 | 47.80 | 254,948 |
27 Feb 24 | Akkaraju Srinivas | Class A Common Stock | Grant | Acquire A | Yes | No | 11.81 | 224,732 | 2.65 mm | 265,620 |
27 Feb 24 | Akkaraju Srinivas | Pre- Funded Warrants Class A Common Stock | Grant | Acquire A | Yes | No | 11.8 | 833,693 | 9.84 mm | 833,693 |
News
vTv Therapeutics Q4 EPS $(1.67) Up From $(2.28) YoY
13 Mar 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
5 Mar 24
S&P 500 Edges Lower; ADT Posts Upbeat Earnings
28 Feb 24
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
28 Feb 24
Why Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today?
28 Feb 24